Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Early results from the phase 2 RESTORE-PV trial suggest that the investigational monoclonal antibody DISC-3405 has the ...

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...

Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials ...

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

In the patient-only intervention group, the rate of skin self-examination and physician skin examination increased from 15.8% at baseline to 47.5% at 12 months; in the group that also had outreach to ...

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Dr Saro Armenian explains.

An interim analysis of a phase 2b trial (NCT04974008) showed a 3-year OS rate of 71.2% among OST-HER2–treated patients compared with 45.8% in a comparable combined historical control group (90% CI, 11 ...

SOHO-01 used blinded independent central review per RECIST v1.1 and enrolled locally advanced/metastatic nonsquamous NSCLC ...

Martin Dietrich, MD, PhD, says the first move at progression is to extend frontline therapy rather than abandon it, looking ...

Sex-stratified outputs showed similar overdiagnosis proportions but higher absolute rates in women, yielding an estimated 443 ...

Wade Iams, MD, says progression-free survival (PFS) drives his frontline choice, since median overall survival remains years ...